

Gregory P Bisson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11782394/publications.pdf>

Version: 2024-02-01

57
papers

2,318
citations

304368

22
h-index

214527

47
g-index

58
all docs

58
docs citations

58
times ranked

3267
citing authors

#	ARTICLE	IF	CITATIONS
1	Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	3
2	Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis. <i>BMC Pulmonary Medicine</i> , 2021, 21, 19.	0.8	9
3	Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy. <i>Clinical Infectious Diseases</i> , 2021, 73, e870-e877.	2.9	4
4	Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. <i>Frontiers in Immunology</i> , 2021, 12, 676980.	2.2	12
5	Outcomes for Clinical Trials of Host-Directed Therapies for Tuberculosis. , 2021, , 295-310.		0
6	Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1845-1854.	2.9	14
7	A Common NLRC4 Gene Variant Associates With Inflammation and Pulmonary Function in Human Immunodeficiency Virus and Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 924-932.	2.9	17
8	A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, 2645-2654.	2.9	11
9	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. <i>Lancet, The</i> , 2020, 396, 402-411.	6.3	49
10	Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1103.	1.6	1
11	Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome. <i>Clinical Infectious Diseases</i> , 2020, 70, 1750-1753.	2.9	10
12	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 393-401.	2.9	62
13	Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2994-3002.	1.3	6
14	Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 179-187.	0.6	5
15	The Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome (TB-IRIS). , 2019, , 99-125.		1
16	Tuberculosis and lung damage: from epidemiology to pathophysiology. <i>European Respiratory Review</i> , 2018, 27, 170077.	3.0	279
17	Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 54-61.	0.9	17
18	Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2018, 68, 18-23.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452
20	Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana. <i>Pharmacogenomics Journal</i> , 2018, 18, 678-688.	0.9	12
21	Common Variation in NLRP3 Is Associated With Early Death and Elevated Inflammasome Biomarkers Among Advanced HIV/TB Co-infected Patients in Botswana. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy075.	0.4	14
22	Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2020-2027.	1.3	6
23	Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 488-491.	0.9	10
24	Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. <i>Aids</i> , 2017, 31, 2217-2225.	1.0	37
25	CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana. <i>Aids</i> , 2017, 31, 2107-2113.	1.0	15
26	Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 801-811.	1.1	19
27	Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study. <i>Addiction</i> , 2017, 112, 73-81.	1.7	14
28	Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. <i>Diabetes Care</i> , 2017, 40, 218-225.	4.3	13
29	Elevated Pre-“Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 1453-1456.	2.9	6
30	Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. <i>PLoS ONE</i> , 2017, 12, e0187624.	1.1	12
31	Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. <i>BMC Infectious Diseases</i> , 2016, 16, 242.	1.3	13
32	Matrix Metalloproteinases in Tuberculosis-Immune Reconstitution Inflammatory Syndrome and Impaired Lung Function Among Advanced HIV/TB Co-infected Patients Initiating Antiretroviral Therapy. <i>EBioMedicine</i> , 2016, 3, 100-107.	2.7	36
33	Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4 ⁺ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. <i>Clinical Infectious Diseases</i> , 2016, 62, 795-803.	2.9	38
34	Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1198-1209.	6.3	70
35	CD4 Cell Counts at Antiretroviral Therapy Initiation in Botswana Have Been Increasing. <i>Clinical Infectious Diseases</i> , 2016, 62, 669-670.	2.9	3
36	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 276.	0.7	22

#	ARTICLE	IF	CITATIONS
37	To have and have not: dissecting protective and pathologic immune recovery in TB-IRIS. <i>Future Virology</i> , 2015, 10, 1217-1229.	0.9	0
38	Persistent High Mortality in Advanced HIV/TB Despite Appropriate Antiretroviral and Antitubercular Therapy: an Emerging Challenge. <i>Current HIV/AIDS Reports</i> , 2015, 12, 107-116.	1.1	24
39	Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. <i>Lancet Infectious Diseases</i> . The. 2015. 15. 429-438.	4.6	73
40	Early Immunologic Failure is Associated With Early Mortality Among Advanced HIV-Infected Adults Initiating Antiretroviral Therapy With Active Tuberculosis. <i>Journal of Infectious Diseases</i> , 2013, 208, 1784-1793.	1.9	25
41	Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2013, 56, 1165-1173.	2.9	81
42	HIV infection and glycemic response to newly initiated diabetic medical therapy. <i>Aids</i> , 2012, 26, 2087-2095.	1.0	23
43	Isoniazid-Resistant Tuberculous Meningitis, United States, 1993-2005. <i>Emerging Infectious Diseases</i> , 2011, 17, 539-542.	2.0	18
44	Early Mortality and AIDS Progression Despite High Initial Antiretroviral Therapy Adherence and Virologic Suppression in Botswana. <i>PLoS ONE</i> , 2011, 6, e20010.	1.1	15
45	A Simple Novel Method for Determining Mortality Rates in HIV Treatment Programs Worldwide. <i>PLoS Medicine</i> , 2011, 8, e1000392.	3.9	0
46	Early Mortality in Adults Initiating Antiretroviral Therapy (ART) in Low- and Middle-Income Countries (LMIC): A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e28691.	1.1	195
47	Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. <i>BMJ: British Medical Journal</i> , 2010, 341, c4451-c4451.	2.4	47
48	In-hospital mortality of HIV-infected cryptococcal meningitis patients with <i>C. gattii</i> and <i>C. neoformans</i> infection in Gaborone, Botswana. <i>Medical Mycology</i> , 2010, 48, 1112-1115.	0.3	42
49	Lost but Not Forgotten- The Economics of Improving Patient Retention in AIDS Treatment Programs. <i>PLoS Medicine</i> , 2009, 6, e1000174.	3.9	15
50	The Use of HAART Is Associated With Decreased Risk of Death During Initial Treatment of Cryptococcal Meningitis in Adults in Botswana. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 227-229.	0.9	44
51	Antiretroviral Failure Despite High Levels of Adherence: Discordant Adherence-Response Relationship in Botswana. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 107-110.	0.9	40
52	Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy. <i>PLoS Medicine</i> , 2008, 5, e109.	3.9	145
53	Overestimates of Survival after HAART: Implications for Global Scale-Up Efforts. <i>PLoS ONE</i> , 2008, 3, e1725.	1.1	107
54	Cryptococcus and lymphocytic meningitis in Botswana. <i>South African Medical Journal</i> , 2008, 98, 724-5.	0.2	11

#	ARTICLE	IF	CITATIONS
55	Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. <i>Aids</i> , 2006, 20, 1333-1336.	1.0	29
56	Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. <i>Aids</i> , 2006, 20, 1613-1619.	1.0	64
57	Effect of GB virus C viremia on HIV acquisition and HIV set-point. <i>Aids</i> , 2005, 19, 1910-1912.	1.0	11